Kinga Gecse (Budapest/ HU), Tamás Nagy (Budapest/ HU), Zsuzsanna Környei (Budapest/ HU), Ádám Dénes (Budapest/ HU), Gyorgy Bagdy (Budapest/ HU), Gabriella Juhasz (Budapest/ HU)
Abstract text (incl. figure legends and references)
Introduction: The regulated on activation and normal T-cell expressed and secreted (RANTES/CCL5) is a chemotactic protein that beyond to chemoattraction is involved in nociception and trigeminal pain. Previous study demonstrated an increased serum RANTES/CCL5 concentration in migraineurs during migraine attack. Additionally, higher RANTES/CCL5 concentration distinguish migraine patients compared to tension-type headache patients. However, the RANTES/CCL5 concentration in headache-free period of migraineurs is contradictory in the literature.
Methods: Blood samples were collected in two independent time-points to measure plasma RANTES/CCL5 concentration of 21 females with episodic migraine without aura and 22 healthy control females The difference in plasma RANTES/CCL5 between migraine and control group was calculated with Mann-Whitney U-test using SPSS27.
Results: RANTES/CCL5 concentration were decreased in migraine patients compared[K1] to healthy controls in both blood samplings (1.BS: U=329, p=0.017; 2.BS: U=312, p=0.049).
Conclusion: Previous studies reported that lower RANTES/CCL5 concentration was associated with higher flow-mediated dilation in vessels. Thus, the decreased serum RANTES/CCL5 concentration replicated in two independent measures may be the sign of vascular hypersensitivity in migraine patients between attacks. The decreased RANTES/CCL5 concentration in interictal period may be a predisposing factor for migraine attack, while the increased RANTES/CCL5 concentration might be associated with migraine pain in ictal period. These findings suggest that RANTES/CCL5 might play a complex role in migraine pathophysiology through its pro-inflammatory, nociceptive and vascular effects that should be further explored.
Funding:EFOP-3.6.3-VEKOP-16-2017-00009; 2017-1.2.1-NKP-2017-00002, KTIA_13_NAPA-II/14, KTIA_NAP_13-1-2013- 0001, KTIA_NAP_13-2- 2015-0001; 2020-4.1.1.-TKP2020; TKP2021-EGA-25; 2019-2.1.7-ERA-NET-2020-00005.